Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep?
Over the past 3 years, since Citron’s Andrew Left made a name for himself as the crusading analyst who helped take down Valeant with an exposé on its shady ties to the specialty pharma Philidor, he and the firm have tackled a series of big players — with a surefire approach to carving up the stock price.
The Valeant takedown became a model for biotech short attacks. And Citron found plenty of leverage as it went after some much bigger game.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
